Meta-analysis of the impact of serum phosphorus reduction on the prognosis of non-dialysis CKD patients: evidence based on clinical outcomes.
Yizhe Xin, Rujia Wang, Ying Guo et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis assessed whether active serum phosphorus reduction affects clinical outcomes in non-dialysis CKD. It included 27 randomized controlled trials involving 3149 patients, identified from Chinese and English databases through August 2025. The pooled results associated active phosphorus reduction with slower renal progression, lower all-cause mortality (RR, 0.52; 95% CI 0.35-0.75; heterogeneity I 2 = 0%), and reduced risk of entering dialysis (RR, 0.60; 95% CI 0.48-0.75; heterogeneity I 2 = 0%). Trials were also grouped by achieved phosphorus reduction rather than intervention type.
Key findings
- Active phosphorus reduction was associated with lower all-cause mortality (RR, 0.52; 95% CI 0.35-0.75; heterogeneity I 2 = 0%).
- The risk of entering dialysis was lower with active phosphorus reduction (RR, 0.60; 95% CI 0.48-0.75; heterogeneity I 2 = 0%).
- The meta-analysis reported delayed renal progression among non-dialysis CKD patients receiving active phosphorus reduction.
Why it matters
The analysis addresses a clinically important evidence gap by focusing on mortality and renal progression rather than relying only on changes in serum phosphorus or PTH. Its findings suggest that phosphorus-lowering may be relevant to outcomes before dialysis, although the pooled results should be interpreted in light of the evidence base and the way treatment groups were classified.
What to keep in mind
The abstract does not report details of trial quality or follow-up. Grouping by achieved phosphorus reduction rather than intervention type may also limit interpretation of the pooled treatment effects.